Last Name


John Somberg to Risk Factors

This is a "connection" page, showing publications John Somberg has written about Risk Factors.

Connection Strength
  1. Somberg J, Molnar J. Adverse Reactions of Amiodarone on the Thyroid. Cardiology. 2016; 134(3):364-5.
    View in: PubMed
    Score: 0.115
  2. Somberg JC. Proposed accelerated FDA approvals for special medical use. Am J Ther. 2012 Nov; 19(6):393-4.
    View in: PubMed
    Score: 0.091
  3. Somberg JC. The impact of comorbidities on stroke prophylaxis strategies in atrial fibrillation patients. Am J Ther. 2011 Nov; 18(6):510-7.
    View in: PubMed
    Score: 0.085
  4. Molnar J, Somberg JC. QT dispersion: still a useful measurement. Cardiology. 2009; 112(3):165-7.
    View in: PubMed
    Score: 0.067
  5. Somberg J. Screening drugs for QT prolongation. Am J Ther. 2007 Sep-Oct; 14(5):419-20.
    View in: PubMed
    Score: 0.063
  6. Somberg JC. SARS challenges therapeutics. Am J Ther. 2003 May-Jun; 10(3):161.
    View in: PubMed
    Score: 0.047
  7. Ranade V, Molnar J, Khokher T, Agarwal A, Mosnaim A, Somberg JC. Effect of angiotensin-converting enzyme therapy on QT interval dispersion. Am J Ther. 1999 Sep; 6(5):257-61.
    View in: PubMed
    Score: 0.036
  8. Kerin NZ, Somberg J. Proarrhythmia: definition, risk factors, causes, treatment, and controversies. Am Heart J. 1994 Sep; 128(3):575-85.
    View in: PubMed
    Score: 0.026
  9. Wolf ME, Ranade V, Molnar J, Somberg J, Mosnaim AD. Hypercalcemia, arrhythmia, and mood stabilizers. J Clin Psychopharmacol. 2000 Apr; 20(2):260-4.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.